Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/12/2009

ATLANTA, March 12 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company focused on development of an HIV/AIDS vaccine, today announced its financial results for the fourth quarter and year ended December 31, 2008, and provided a summary of recent operational highlights for calendar year 2009 to date.

GeoVax reported a net loss of $1,039,217 for the fourth quarter ended December 31, 2008, as compared to a net loss of $1,155,870 for the comparable period in 2007. For the full year of 2008, the Company reported a net loss of $3,728,187 as compared to a net loss of $4,241,796 in 2007. GeoVax's operating results fluctuate due to the timing of activities and related costs associated with its vaccine research and development activities. Summarized financial information is presented below. GeoVax's full set of audited financial statements are included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Robert T. McNally, Ph.D., GeoVax's president and chief executive officer, stated, "For a company of GeoVax's size and stage of clinical development, our financial position is on target. Our operational expenses are reduced by the National Institutes of Health's (NIH) support of our ongoing Phase 2a preventative clinical trial being conducted by the HIV Vaccine Trials Network (HVTN), and are further offset by the direct grant from the NIH to GeoVax, covering research and development for future vaccine improvements. Our financial security is enhanced by the common stock purchase agreement with Fusion Capital Fund II, LLC. These funds are providing the Company with resources to conduct its own clinical trial in HIV infected, drug controlled subjects. Planning for this therapeutic trial is underway with a projected start for later this year."

            Recent Operational Highlights for Year 2009 - to date

    
'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
2. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
3. GeoVax to Present at the BIO CEO & Investor Conference 2009
4. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
5. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
8. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
9. GeoVax Further Strengthens Management Team
10. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
11. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... and SAN JOSE, California , January ... company developing antibody-drug conjugates for cancer, today announced the appointment ... Directors. Dr Reynolds has over 20 years, development experience gained ... at Seattle Genetics. "I am delighted to welcome ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... VIEW, Calif., Nov. 7, 2011 VIVUS, Inc. (NASDAQ: ... and commercialization of novel therapeutic products, today reported its financial ... 30, 2011. Third Quarter ResultsFor the ... loss of $8.6 million, or $0.10 net loss per share, ...
... November 7, 2011 Note: numbers in square ... Boulter is available for interview. Investment fund manager ... today won a court battle with 3M over the multi-national ... The High Court in London found 3M was ...
... HANOVER, N.J., Nov. 7, 2011 Novartis announced today ... with active systemic juvenile idiopathic arthritis (SJIA) were able ... described as steroids) within 28 weeks of commencing treatment ... of the study, which met both primary endpoints, will ...
Cached Biology Technology:VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 2VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 3VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 4VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 5VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 6VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 7VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 8VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results 93M Forced to Pay for Breach of Obligations Over MRSA - High Court 23M Forced to Pay for Breach of Obligations Over MRSA - High Court 33M Forced to Pay for Breach of Obligations Over MRSA - High Court 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 2Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 3Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 4Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 5Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 6Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis 7
(Date:4/17/2014)... MANHATTAN, KAN. A Kansas State University engineer ... security and remotely detects improvised explosive devices. The ... , William Dunn, the Steven M. and Kay ... of mechanical and nuclear engineering, and his research ... explosives hidden underground or in car trunks. The ...
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... 2012 Chiltern International Limited (Chiltern), a global contract ... James Gunter have joined Chiltern, bringing their expertise in ... strengthen our Global Clinical Development services. ... Cedric Burg has been appointed to the position of ...
... pests by using ultrasonic frequencies are available and marketed ... been demonstrated as being effective in repelling insect pests ... of evidence for the efficacy of such devices, they ... bugs are readily available. However, according to a ...
... reprogramming a 7-year-old girl,s own immune cells to attack ... has achieved a complete response in his patient, who ... The innovative experimental therapy used bioengineered T cells, custom-designed ... leukemia cells. After the treatment, the child,s doctors found ...
Cached Biology News:Chiltern Welcomes Cedric Burg And James Gunter 2Engineered immune cells produce complete response in child with an aggressive pediatric leukemia 2Engineered immune cells produce complete response in child with an aggressive pediatric leukemia 3
... cultured in DMEM with 4 mM L-glutamine medium ... In order to keep the antigens in ... The cells are arrayed on a 12-well ... surface specifically treated to enhance cellular attachment and ...
... cultured in DMEM and harvested at the log ... the antigens in their native forms, cells were ... on a 12-well (5 mm) adhesive coated slide, ... cellular attachment and to minimize background staining. ...
... P815 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
...
Biology Products: